Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cbd epilepsy:

CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Tzadok M et al. Seizure. (2016)

Cannabinoids in treatment-resistant epilepsy: A review. O'Connell BK et al. Epilepsy Behav. (2017)

The Pharmacological Basis of Cannabis Therapy for Epilepsy. Reddy DS et al. J Pharmacol Exp Ther. (2016)

Search results

Items: 1 to 20 of 131

1.

Cannabis Therapeutics and the Future of Neurology.

Russo EB.

Front Integr Neurosci. 2018 Oct 18;12:51. doi: 10.3389/fnint.2018.00051. eCollection 2018.

2.

Efficacy of cannabinoids in paediatric epilepsy.

Ali S, Scheffer IE, Sadleir LG.

Dev Med Child Neurol. 2018 Nov 6. doi: 10.1111/dmcn.14087. [Epub ahead of print] Review.

PMID:
30402932
3.

Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.

Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, Silvestrini M.

Drugs. 2018 Nov 3. doi: 10.1007/s40265-018-0992-5. [Epub ahead of print] Review.

PMID:
30390221
4.

Quantification of Eight Cannabinoids Including Cannabidiol in Human Urine Via Liquid Chromatography Tandem Mass Spectrometry.

Scheidweiler KB, Barnes AJ.

Methods Mol Biol. 2019;1872:11-22. doi: 10.1007/978-1-4939-8823-5_2.

PMID:
30350275
5.

Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells.

Russo C, Ferk F, Mišík M, Ropek N, Nersesyan A, Mejri D, Holzmann K, Lavorgna M, Isidori M, Knasmüller S.

Arch Toxicol. 2018 Oct 19. doi: 10.1007/s00204-018-2322-9. [Epub ahead of print]

PMID:
30341733
6.

Pathophysiology of corticobasal degeneration: Insights from neurophysiological studies.

Nardone R, Brigo F, Versace V, Sebastianelli L, Christova M, Golaszewski S, Saltuari L, Trinka E.

J Clin Neurosci. 2018 Oct 13. pii: S0967-5868(18)30828-2. doi: 10.1016/j.jocn.2018.10.027. [Epub ahead of print]

PMID:
30327223
7.

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.

Crippa JA, Guimarães FS, Campos AC, Zuardi AW.

Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018. Review.

8.

Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.

Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, Etges T, Sommerville K.

Epilepsy Behav. 2018 Oct 1;88:162-171. doi: 10.1016/j.yebeh.2018.07.027. [Epub ahead of print]

9.

Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis.

Pamplona FA, da Silva LR, Coan AC.

Front Neurol. 2018 Sep 12;9:759. doi: 10.3389/fneur.2018.00759. eCollection 2018.

10.

Cannabidiol for Treatment of Childhood Epilepsy-A Cross-Sectional Survey.

Klotz KA, Schulze-Bonhage A, Antonio-Arce VS, Jacobs J.

Front Neurol. 2018 Sep 7;9:731. doi: 10.3389/fneur.2018.00731. eCollection 2018.

11.

A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome.

McCoy B, Wang L, Zak M, Al-Mehmadi S, Kabir N, Alhadid K, McDonald K, Zhang G, Sharma R, Whitney R, Sinopoli K, Snead OC 3rd.

Ann Clin Transl Neurol. 2018 Aug 1;5(9):1077-1088. doi: 10.1002/acn3.621. eCollection 2018 Sep.

12.

Marijuana's Effects on Brain Structure and Function: What Do We Know and What Should We Do? A Brief Review and Commentary.

deShazo RD, Parker SB, Williams D, Ingram JB, Elsohly M, Rodenmeyer K, McCullouch K.

Am J Med. 2018 Sep 18. pii: S0002-9343(18)30872-6. doi: 10.1016/j.amjmed.2018.09.006. [Epub ahead of print] Review.

PMID:
30240677
13.

Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor.

Rodríguez-Muñoz M, Onetti Y, Cortés-Montero E, Garzón J, Sánchez-Blázquez P.

Mol Brain. 2018 Sep 17;11(1):51. doi: 10.1186/s13041-018-0395-2.

14.

Inhibitory effects of cannabidiol on voltage-dependent sodium currents.

Ghovanloo MR, Shuart NG, Mezeyova J, Dean RA, Ruben PC, Goodchild SJ.

J Biol Chem. 2018 Oct 26;293(43):16546-16558. doi: 10.1074/jbc.RA118.004929. Epub 2018 Sep 14.

15.

Cannabis for the Treatment of Epilepsy: an Update.

Gaston TE, Szaflarski JP.

Curr Neurol Neurosci Rep. 2018 Sep 8;18(11):73. doi: 10.1007/s11910-018-0882-y. Review.

PMID:
30194563
16.

Cannabidiol as a suggested candidate for treatment of autism spectrum disorder.

Poleg S, Golubchik P, Offen D, Weizman A.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 29;89:90-96. doi: 10.1016/j.pnpbp.2018.08.030. [Epub ahead of print] Review.

PMID:
30171992
17.

Anticonvulsant and Neuroprotective Effects of Cannabidiol During the Juvenile Period.

Friedman LK, Wongvravit JP.

J Neuropathol Exp Neurol. 2018 Oct 1;77(10):904-919. doi: 10.1093/jnen/nly069.

PMID:
30169677
18.

Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System.

Schonhofen P, Bristot IJ, Crippa JA, Hallak JEC, Zuardi AW, Parsons RB, Klamt F.

CNS Drugs. 2018 Aug;32(8):697-712. doi: 10.1007/s40263-018-0550-4.

PMID:
30109642
19.

Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.

Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, Dure LS, Gaston TE, Kankirawatana P, Liu Y, Singh R, Standaert DG, Thomas AE, Ver Hoef LW; UAB CBD Program.

Epilepsy Behav. 2018 Aug 9. pii: S1525-5050(18)30473-6. doi: 10.1016/j.yebeh.2018.07.020. [Epub ahead of print]

20.

Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.

Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, Szaflarski JP, Wilfong A, Clark GD, Park YD, Seltzer LE, Bebin EM, Flamini R, Wechsler RT, Friedman D.

Epilepsy Behav. 2018 Sep;86:131-137. doi: 10.1016/j.yebeh.2018.05.013. Epub 2018 Jul 11.

Supplemental Content

Loading ...
Support Center